Genmab report positive results from Phase III daratumumab trial for myeloma patients

The Danish biotechnology company, Genmab, have announced that the Phase III trial, ALCYONE, has achieved its primary endpoint of improving progression-free survival in newly diagnosed myeloma patients. This study compared daratumumab (Darzalex®) in combination with bortezomib (Velcade®), melphalan and prednisone (VMP) to VMP alone. Treatment including daratumumab was demonstrated to reduce the risk of disease…

Details
News

Carfilzomib combination approved for use in Scotland

The Scottish Medicines Consortium (SMC) has approved the use of carfilzomib (Kyprolis®) in combination with dexamethasone for myeloma patients who have received at least one previous treatment. The approval is based on results from the ENDEAVOR trial which showed that progression-free survival was significantly improved in patients treated with carfilzomib in combination with dexamethasone compared…

Details
News

Lenalidomide maintenance treatment demonstrates significant overall survival benefit following HDT-ASCT

Meta-analysis of results from three randomised control trials has demonstrated that maintenance treatment with lenalidomide (Revlimid®) following high-dose therapy and autologous stem cell transplantation (HDT-ASCT) in newly diagnosed myeloma patients has a significant overall survival (OS) benefit. Published in the Journal of Clinical Oncology, the results of this meta-analysis, which used data pooled from the…

Details
News

Supportive treatments

The Role of Low-dose Anti-thymocyte Globulin as Standard Prophylaxis in Mismatched and Matched Unrelated Hematopoietic Peripheral Stem Cell Transplantation for Hematologic Malignancies. Sakellari I et al. Clin Lymphoma Myeloma Leuk. 2017 Jun 29. pii: S2152-2650(17)30096-4. doi: 10.1016/j.clml.2017.06.008. [Epub ahead of print]. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis in Multiple Myeloma. Ghosh N et al. Biol Blood Marrow…

Details
Journal, Library, Myeloma Prognosis & Outcomes

Related conditions

Congestive Heart Failure with Preserved Ejection Fraction in a Patient with Light Chain (AL) Amyloidosis and Multiple Myeloma. Carrizales-Sepúlveda EF et al. Am J Case Rep. 2017 Jul 13;18:790-793. Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts. Meziane I et al. Haematologica. 2017 Jul 4. pii: haematol.2017.171108. doi: 10.3324/haematol.2017.171108. [Epub ahead of print]. Monoclonal Gammopathy…

Details
Journal, Library

General

Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) was established using traditional, generalizability and Rasch psychometric methods. Ramsenthaler C et al. Qual Life Res. 2017 Jul 27. doi: 10.1007/s11136-017-1660-z. [Epub ahead of print]. The Experience of Myeloma Caregivers During Home-Based Oral Chemotherapy Treatment: A Qualitative Study. Morris M et al. Semin Oncol Nurs. 2017 Jul 24. pii: S0749-2081(17)30045-1. doi: 10.1016/j.soncn.2017.05.010. [Epub ahead…

Details
Journal, Library

Emerging treatments

CAR-Ts move beyond B-cell cancers to myeloma. Dolgin E. Nat Biotechnol. 2017 Jul 12;35(7):599-601. doi: 10.1038/nbt0717-599. The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma. Brayer J et al. Ther Adv Hematol. 2017 Jul;8(7):209-220. doi: 10.1177/2040620717710171. Epub 2017 Jun 28. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation…

Details
Journal, Library